<DOC>
	<DOC>NCT00150254</DOC>
	<brief_summary>The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018</brief_summary>
	<brief_title>12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.</brief_title>
	<detailed_description />
	<mesh_term>Varenicline</mesh_term>
	<criteria>Subjects must have smoked on average of at least ten cigarettes per day during the past year Subjects must have no period of abstinence greater than three months in the past year Subjects with any history of clinically significant cardiovascular disease Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>